A humanized antibody targeting this TAA, PRL3-zumab, was demonstrated to promote recruitment of B cells, NK cells and macrophages, which suggests that this therapy might promote tumor killing by antibody-dependent, cell-mediated cytotoxicity [100]. The gene discussed is PTP4A3; the disease is neoplasm.